Emcure Pharmaceuticals (EMCURE) — Annual Report

📢 Key Event
Emcure Pharmaceuticals filed its 2025-26 Annual Report with BSE on 28 August 2026, highlighting FY2026 financial performance and strategic outlook.

🔄 What Changed
Revenue grew 16.6% YoY to INR 92,035 Mn; EBITDA margin expanded to 19.4% (up 80 bps); PAT grew 33.1% to INR 9,413 Mn; international revenue grew 22.2% to INR 51,766 Mn; R&D investment remained at 4.2% of revenue.

🔮 What's Next
Targeting low-to-mid-teens revenue growth and 75-100 bps EBITDA margin expansion for FY 2026-27, supported by strong free cash flow for deleveraging.

💡 Investor Takeaway
Emcure is executing a focused growth strategy on domestic chronic therapies and international markets, with strong financial momentum and clear targets for margin expansion and deleveraging, making it a compelling growth story in specialty pharma.

Emcure Pharmaceuticals' 2025-26 Annual Report (Reg. 34 (1)) filed on BSE on 28 August 2026, details FY2026 performance with revenue of INR 92,035 Mn (16.6% YoY growth), EBITDA margin expansion to 19.4% (up 80 bps), and PAT growth of 33.1% to INR 9,413 Mn. The report highlights strategic focus on domestic chronic therapy growth, international expansion (22.2% revenue growth), and R&D investment at 4.2% of sales. Key initiatives include the Novo Nordisk semaglutide partnership, Zuventus acquisition integration, and pipeline advancements in biosimilars and complex injectables. The company targets low-to-mid-teens revenue growth and 75-100 bps EBITDA margin expansion for FY 2026-27, supported by deleveraging via free cash flow. Governance updates include new independent director appointments, AGM scheduled for 21 September 2026 via video conferencing, and e-voting from 18-20 September 2026. No material related party transactions were identified.

📄 View Original Announcement (PDF)

📊 Stock Analysis — EMCURE ✨ Ask AI About This

About Emcure Pharmaceuticals Ltd (EMCURE)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹35,011.16 Cr P/E: 34.6 ROE: 22.9% ROCE: 29.7% Div Yield: 0.20%

View full EMCURE stock details →

📡 Get AI alerts when EMCURE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track EMCURE — Free

💡 Ask AI about this filing

"What is Emcure's target EBITDA margin for FY 2026-27?" "How much of Emcure's revenue comes from international markets?" "What is the status of Emcure's semaglutide partnership with Novo Nordisk?"

Ask AI Free →

📊 More EMCURE filings

See all EMCURE filings →

🔥 Also filed on 28 August 2026

BLIL Balmer Lawrie Investment Ltd Annual Report 520075 Samkrg Pistons & Rings Ltd Annual Report 507998 Simmonds Marshall Ltd Annual Report BLUEDART Blue Dart Express Ltd Annual Report TTL T T Ltd Insider Trading LTF L&T Finance Ltd Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when EMCURE files new disclosures

Track EMCURE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track EMCURE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd